Median’s eyonis LCS is being evaluated as a tool to help assess the likelihood that a lung lesion detected on low-dose CT is malignant, Oran Muduroglu, founder and CEO of Coeus Health, said in an ...

In new case study, CyPath Lung spares elderly woman from an invasive procedure for a suspicious lung nodule discovered on a ...

A state-led AI screening drive flags hidden tumours early and sparks national scale-up talks ...

SAN ANTONIO, Texas, February 17, 2026--bioAffinity Technologies shares a new case study that demonstrates how CyPath® Lung supports clinical decision-making in high-risk patients.

Shira Boehler shares her journey being diagnosed with Stage 1 lung cancer. A doctor explains the need for better lung cancer screening for asymptomatic, never smokers.

Background Prospective validation and comparison of the performance of nodule management protocols is limited. The aim of this study was to examine the performance of size and risk thresholds for ...

Lung cancer remains the leading cause of cancer-related mortality worldwide. Early detection of pulmonary nodules is crucial for timely diagnosis and effective treatment.

The proposed CNN-based system demonstrates the feasibility and robustness of deep learning for automatic lung nodule detection and classification. Despite strong results, the study acknowledges ...

Lung cancer remains the leading cause of cancer-related mortality worldwide. Early detection of pulmonary nodules is crucial for timely diagnosis and ...

The US Food and Drug Administration (FDA) has granted marketing clearance to Eyonis LCS, an artificial intelligence-powered ...

Affinity Technologies, Inc. , a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced new appointments to its Medical and Scientific Advisory Board, ...